Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: A retrospective analysis

BMC Cancer

Volumn 17, Issue 1, 2017, Pages

  Liu, Dan ^a   Li, Jian ^a   Gao, Jing ^a   Li, Yanyan ^a   Yang, Rui ^a   Shen, Lin ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Clinical response; DPYD polymorphisms; Irinotecan; Metastatic colorectal cancer; Toxicity; UGT1A polymorphisms

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A9; IRINOTECAN; OXALIPLATIN; TEGAFUR; UNCLASSIFIED DRUG; CAMPTOTHECIN; PHARMACOLOGICAL BIOMARKER; UGT1A1 ENZYME;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CHINESE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DPYD GENE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; MUTATION RATE; MUTATIONAL ANALYSIS; NEUTROPENIA; OVERALL SURVIVAL; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SURVIVAL TIME; TREATMENT RESPONSE; UGT1A GENE; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COLORECTAL TUMOR; GENETIC ASSOCIATION STUDY; GENETICS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BIOMARKERS, PHARMACOLOGICAL; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIARRHEA; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED;

EID: 85021066643     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-017-3406-2     Document Type: Article

References (36)

1. Garcia-Alfonso P, Chaves M, Muñoz A, et al. Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. BMC Cancer. 2015;15(1):1-9.
2. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med. 2000;343(13):905-14.
3. Lamas MJ, Duran G, Balboa E, et al. The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens. Cancer Chemother Pharmacol. 2012;69(6):1591-9.
4. Miyata Y, Touyama T, Kusumi T, et al. UDP-glucuronosyltrans-ferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer. Int J Clin Oncol. 2016;21(4):696-703.
5. Gao J, Zhou J, Li Y, et al. UGT1A1*6/*28 polymorphisms could predict irinotecan induced severe neutropenia not diarrhea in Chinese colorectal cancer patients. Med Oncol. 2013;30(3):1-6.
6. Cheng L, Li M, Hu J, et al. UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians. Cancer Chemother Pharmacol. 2014;73(3):551-60.
7. Tsunedomi R, Hazama S, Fujita Y, et al. A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes. Int J Oncol. 2014;45(4):1381-90.
8. Mego M, Chovanec J, Vochyanova-Andrezalova I, et al. Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study. Complement Ther Med. 2015;23(3):356-62.
9. Yan L, Wang XF, Wei LM, et al. Effects of UGT1A1*6, UGT1A1*6;54(3):193-9.
10. Sunakawa Y, Ichikawa W, Fujita K, et al. UGT1A1*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2011;68(2):279-84.
11. Gentile G, Botticelli A, Lionetto L, et al. Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction. Pharmacogenomics J. 2016;16(4):320-5.
12. Mazzuca F, Borro M, Botticelli A, et al. Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort. Oncotarget. 2016;7(15):20612-20.
13. Etienne-Grimaldi MC, Boyer JC, Thomas F, et al. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundam Clin Pharmacol. 2015;29(3):219-37.
14. Leung HW, Chan AL. Association and prediction of severe 5-fluorouracil toxicity with dihydropyrimidine dehydrogenase gene polymorphisms: a meta-analysis. Biomed Rep. 2015;3(6):879-83.
15. Teh LK, Hamzah S, Hashim H, et al. Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients. Ther Drug Monit. 2013;35(5):624-30.
16. Falvella FS, Cheli S, Martinetti A, et al. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. Br J Clin Pharmacol. 2015;80(3):581-8.
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.
18. Mik M, Berut M, Dziki L, et al. Right- and left-sided colon cancer - clinical and pathological differences of the disease entity in one organ. Arch Med Sci. 2017;13(1):157-62.
19. Sakar B, Gumus M, Basaran M, et al. XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer. Oncology. 2007;73(5-6):298-304.
20. Wang Y, Shen L, Xu N, et al. UGT1A1*6635-44.
21. Li M, Wang Z, Guo J, et al. Clinical significance of UGT1A1*653-61.
22. Xu C, Tang X, Qu Y, et al. UGT1A1*6;78(1):1-12.
23. Atasilp C, Chansriwong P, Sirachainan E, et al. Correlation of UGT1A1*6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients. Drug Metab Pharmacokinet. 2016;31(1):90-4.
24. Shimoyama S. Pharmacogenetics of irinotecan: an ethnicity-based prediction of irinotecan adverse events. World J Gastrointest Surg. 2010;2(1):14-21.
25. Fujita K, Ando Y, Nagashima F, et al. Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother Pharmacol. 2007;60:515-22.
26. Hazama S, Mishima H, Tsunedomi R, et al. UGT1A1*6, 1A7 *3, and 1A9*22 genotypes predict severe neutropenia in FOL-/FIRI-treated metastatic colorectal cancer in two prospective studies in Japan. Cancer Sci. 2013;104(12):1662-9.
27. Tziotou M, Kalotychou V, Ntokou A, et al. Polymorphisms of uridine glucuronosyltransferase gene and irinotecan toxicity: low dose does not protect from toxicity. Ecancermedicalscience. 2014;8:428.
28. Carlini LE, Meropol NJ, Bever J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005;11(3):1226-36.
29. Cecchin E, Innocenti F. D Andrea M, et al. predictive role of the UGT1A1*65.
30. Deenen MJ, Meulendijks D, Cats A, et al. Upfront genotyping of DPYD*2A to individualize Fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2016;34(3):227-34.
31. Sirachainan E, Reungwetwattana T, Wisetpanit Y, et al. Pharmacogenetic study of 5-FU-related severe toxicity in Thai cancer patients: a novel SNP detection. J Pharmacogenomics Pharmacoproteomics. 2012;3:1-4.
32. Zhang XP, Bai ZB, Chen BA, et al. Polymorphisms of dihydropyrimidine dehydrogenase gene and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population. Chin Med J. 2012;125:741-6.
33. Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1*6;24:3061-8.
34. Lu CY, Huang CW, Wu IC, et al. Clinical implication of UGT1A1*6):474-9.
35. Kobayashi M, Hazama S, Takahashi K, et al. Is there diversity among UGT1A1 polymorphism in Japan? World J Gastrointest Oncol. 2012;4(7):170-5.
36. Braun MS, Richman SD, Thompson L, et al. Association of Molecular Markers with Toxicity Outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol. 2009;27(33):5519-28.